This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (5)  • Contact me when this article is cited  Related Content  • Related letters  • Related articles  • Similar articles in this journal  Topic Collections  • Oncology  • Oncology, Other  • Ocular/ Adnexal Tumors  • Prognosis/ Outcomes  • Liver/ Biliary Tract/ Pancreatic Diseases  • Genetics  • Genetic Counseling/ Testing/ Therapy  • Genetic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Jerry A. Shields, MD; Carol L. Shields, MD; Miguel Materin, MD; Takami Sato, MD; Arupa Ganguly, PhD

Arch Ophthalmol. 2008;126(3):416-419.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Uveal melanoma is one of the few conditions diagnosed by eye care specialists that carries a guarded prognosis for life. Although most patients are apparently healthy at the time of diagnosis, 10-year tumor-related death from posterior uveal melanoma ranges from 20% to greater than 50%.^1-3

The management of posterior uveal melanoma has been controversial. Several years ago, heated debates erupted between 2 diametrically opposed schools of thought. One group favored prompt enucleation of virtually all melanocytic uveal lesions that were suspected to be melanomas.^4-5 The other group preferred observation of many small- and medium-sized tumors to document growth before initiating treatment^6-8; they proposed that enucleation might not improve the prognosis and could even accelerate dissemination of the neoplasm.⁶ The philosophy of "observation until growth is documented" has prevailed in ophthalmology during the . . . [Full Text of this Article]

RECENT DEVELOPMENTS IN CYTOGENETICS


CURRENT CLINICAL APPLICATIONS

AUTHOR INFORMATION
Author Affiliations: The Ocular Oncology Service, Wills Eye Institute (Drs J. A. Shields, C. L. Shields, and Materin), and the Department of Medical Oncology (Dr Sato), Thomas Jefferson University; and the Department of Genetics, University of Pennsylvania (Dr Ganguly), Philadelphia, Pennsylvania.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Genomic Typing of Uveal Melanoma
Bertil Damato and Sarah E. Coupland
Arch Ophthalmol. 2009;127(1):113-114.
EXTRACT | FULL TEXT  

Genomic Typing of Uveal Melanoma—Reply
Jerry A. Shields, Carol L. Shields, Miguel Materin, Takami Sato, and Arupa Ganguly
Arch Ophthalmol. 2009;127(1):114.
EXTRACT | FULL TEXT  

Genomic Typing of Uveal Melanoma—Reply
Dennis M. Robertson
Arch Ophthalmol. 2009;127(1):114-115.
EXTRACT | FULL TEXT  

Genomic Typing of Uveal Melanoma—Reply
Tony Tsai and Joan M. O’Brien
Arch Ophthalmol. 2009;127(1):115.
EXTRACT | FULL TEXT  

RELATED ARTICLES

Cytogenetics in the Management of Uveal Melanoma: Are We There Yet?
Dennis M. Robertson
Arch Ophthalmol. 2008;126(3):409-410.
EXTRACT | FULL TEXT  

The Future Promise and the Current Reality of Genetic Prognostication in Patients With Uveal Melanoma
Tony Tsai and Joan M. O’Brien
Arch Ophthalmol. 2008;126(3):413-415.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Choroidal Nevus Transformation Into Melanoma: Analysis of 2514 Consecutive Cases
Shields et al.
Arch Ophthalmol 2009;127:981-987.
ABSTRACT | FULL TEXT  

Genomic Typing of Uveal Melanoma
Damato and Coupland
Arch Ophthalmol 2009;127:113-114.
FULL TEXT  

Genomic Typing of Uveal Melanoma--Reply
Shields et al.
Arch Ophthalmol 2009;127:114-114.
FULL TEXT  

Genomic Typing of Uveal Melanoma--Reply
Robertson
Arch Ophthalmol 2009;127:114-115.
FULL TEXT